AMD linked to increased incidence of death from stroke, cardiovascular events

Article

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Jennifer S. Tan at the University of Sydney, Australia and team assessed 3654 subjects (age ≥49 years), with follow-up at five (n=2335) and 10 (n=1952) years. Assessment included physical risk factors and medical history; causes of death were confirmed by the Australian National Death Index.

Early presentation of AMD was, after adjusting for traditional cardiovascular risk factors, linked to a twofold increase in cardiovascular mortality over a 10-year period in subjects aged <75 years at baseline. Late presentation of AMD was, after adjusting for age and gender, associated with a five times increased incidence of cardiovascular mortality and a 10 times increased incidence of stroke mortality, again in subjects aged <75 years at baseline.

The researchers concluded that this association of AMD with mortality from stroke and cardiovascular events may have implications for intravitreal anti-VEGF therapies, which are also linked with an increased risk of stroke.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.